Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1977 2
1978 1
1979 1
1983 2
1984 1
1985 2
1986 5
1987 5
1988 3
1989 3
1991 2
1992 7
1993 4
1994 5
1995 5
1996 2
1997 3
1999 1
2001 2
2002 2
2003 1
2004 7
2005 2
2006 5
2007 3
2008 3
2009 1
2010 1
2011 2
2012 2
2013 1
2014 1
2015 3
2018 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

91 results
Results by year
Filters applied: . Clear all
Page 1
IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM. Ab O, et al. Among authors: goldmacher vs. Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22. Mol Cancer Ther. 2015. PMID: 25904506
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V. Deckert J, et al. Among authors: goldmacher vs. Clin Cancer Res. 2014 Sep 1;20(17):4574-83. doi: 10.1158/1078-0432.CCR-14-0695. Epub 2014 Jul 1. Clin Cancer Res. 2014. PMID: 24987056
Cell killing by antibody-drug conjugates.
Kovtun YV, Goldmacher VS. Kovtun YV, et al. Among authors: goldmacher vs. Cancer Lett. 2007 Oct 8;255(2):232-40. doi: 10.1016/j.canlet.2007.04.010. Epub 2007 Jun 5. Cancer Lett. 2007. PMID: 17553616 Review.
Cell death suppressors encoded by cytomegalovirus.
Goldmacher VS. Goldmacher VS. Prog Mol Subcell Biol. 2004;36:1-18. doi: 10.1007/978-3-540-74264-7_1. Prog Mol Subcell Biol. 2004. PMID: 15171604 Review. No abstract available.
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, Bai C, Rui L, Laleau R, Liu F, Ab O, Setiady Y, Yoder NC, Goldmacher VS, Chari RVJ, Pinkas J, Chittenden T. Kovtun Y, et al. Among authors: goldmacher vs. Blood Adv. 2018 Apr 24;2(8):848-858. doi: 10.1182/bloodadvances.2018017517. Blood Adv. 2018. PMID: 29661755 Free PMC article.
Antibody-maytansinoid conjugates designed to bypass multidrug resistance.
Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV. Kovtun YV, et al. Among authors: goldmacher vs. Cancer Res. 2010 Mar 15;70(6):2528-37. doi: 10.1158/0008-5472.CAN-09-3546. Epub 2010 Mar 2. Cancer Res. 2010. PMID: 20197459
91 results